Claratyne

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Claratyne

Property Description
Active Ingredient Loratadine
Form Oral tablet, oral syrup, oral capsule, chewable tablet
Pharmacological Class Second-generation H1-Antagonist (Antihistamine)
General Purpose Provides relief from histamine-driven physical discomfort
Origin Synthetic (Piperidine derivative)

Claratyne: Definition and Classification as a Targeted Antihistamine

Claratyne is a pharmaceutical product whose function is centered on the active ingredient Loratadine, classified as a synthetic compound within the therapeutic group of antihistamines. This medicine is specifically categorized as a second-generation H1-receptor antagonist, designed to address the physical consequences of allergic reactions. The Loratadine molecule is a piperidine derivative with the chemical formula C22H23ClN2O2.

The classification as a second-generation agent highlights its structural engineering, which targets peripheral H1 receptors preferentially over those in the central nervous system. This reduced central activity is the reason Claratyne is generally known as a non-sedating option for most users. Its pharmacological profile is clinically recognized for providing effective symptomatic relief with minimal impact on cognitive function.


Composition, Form, and General Purpose

The core composition of the medicine is the Loratadine molecule, supplied as a single-ingredient product intended for oral administration. The medication is available in various forms, including the standard oral tablet, the oral capsule, and an oral syrup, often tailored to different patient groups such as those needing the chewable tablet format.

The fundamental general purpose of this medication is to modulate the body's allergic response by acting as a selective blocker. It prevents the naturally released chemical histamine from binding to its designated receptors, thereby suppressing the resulting physical discomfort. This long-acting mechanism helps mitigate the symptoms associated with allergic reactions, offering the patient sustained systemic relief.

What side effects are possible with Claratyne?

The safety characteristics of Claratyne, which contains the active substance Loratadine, are formally documented in regulatory prescribing information. The majority of reported effects are categorized by their frequency and the system-organ class they affect.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the rate of occurrence reported in clinical trials or post-marketing data. The most Common effects reported in adults and adolescents include headache and somnolence (drowsiness). Reactions categorized as Uncommon include insomnia, nervousness, and dry mouth. In the pediatric population (2 to 12 years), the most frequently reported effects are documented as headache, nervousness, and fatigue.

System-Organ Class and Serious Adverse Reactions

The officially listed reactions involve several System-Organ Classes, including Nervous System Disorders, Gastrointestinal Disorders (such as nausea and gastritis), and Cardiac Disorders (such as tachycardia and palpitation). Very Rare adverse reactions, primarily identified through post-marketing surveillance, include clinically significant events such as anaphylaxis (severe allergic reaction), convulsions (seizures), and signs of abnormal hepatic function.

Safety Considerations and Restrictions

Official labeling includes safety notes for specific populations. Patients with severe hepatic impairment may require a lower initial dose, as liver disease can affect the body's processing of the medicine. A procedural constraint requires that the medicine be discontinued approximately 48 hours prior to allergy skin testing, as its antihistaminic effect may interfere with the test results. Use is strictly restricted in individuals with known hypersensitivity to the active substance or any ingredient.

Overdose and Emergency Response

Claratyne Overdose and When to Seek Help

The official regulatory profile for Loratadine overdose is based on documented cases, primarily involving ingestions exceeding the standard recommended daily amount.

Documented Manifestations and Serious Risks

Overdose presentations reported in regulatory documents commonly include central nervous system (CNS) effects such as somnolence (drowsiness) and headache. Cardiovascular system effects, particularly tachycardia (fast heart rate), are also documented. In cases of massive ingestion, there is a potential risk of severe outcomes including cardiac arrhythmia and prolongation of the QT-interval.

Mandated Emergency Action

In any suspected overdose situation, official guidance mandates that individuals seek immediate medical attention and contact a Poison Control Center without delay. If the individual has collapsed, experienced a seizure, or has trouble breathing, emergency services must be called immediately.

Management and Constraints

Management of Loratadine overdose must focus on general symptomatic and supportive measures because no specific antidote is known. The drug is not effectively removed by haemodialysis. Official procedures include the prompt administration of activated charcoal and may involve gastric lavage for decontamination, requiring hospital monitoring. Specific considerations exist for children, who have reported extrapyramidal signs and palpitations, and the elderly or those with hepatic impairment, who may have altered clearance.

Therapeutic Uses of Claratyne

What Claratyne Treats: Main Uses and Benefits

Claratyne is used to provide symptomatic support for various allergic conditions. It is designed to assist with easing symptoms that commonly interfere with daily functioning and routine activities.


Core Therapeutic Focus

This medication is commonly used to help temporarily ease symptoms associated with recurrent or episodic manifestations of allergies, including sneezing, runny nose, itchiness, and tearing of the eyes. It is also used in contexts involving skin reactions, such as managing symptoms associated with hives (chronic idiopathic urticaria).

The primary benefit is that this supportive relief contributes to improved comfort during periods of heightened symptoms. It helps individuals manage symptom fluctuations more steadily, providing a sense of stability. The overarching goal is to ease the symptomatic load in scenarios where symptoms become temporarily overwhelming.

“This supportive approach assists with maintaining functional stability when symptoms interfere with routine activities.”


Quick Fact: Relief for Allergy Symptom Clusters

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Claratyne — Official Regulatory Information

Contraindications

The medicine is contraindicated in patients with known hypersensitivity to the active substance loratadine or to any of its excipients. Use in children under 2 years of age is generally not established and is discouraged or contraindicated.


Age-Related Eligibility

Age Group Eligibility Status (as stated in label)
Adults & Adolescents (12 years and over) Generally allowed for standard use.
Children 6 to 11 years Approved for use (typically tablets).
Children 2 to 5 years Approved for use (typically oral solution/syrup).
Children under 2 years Contraindicated; safety and efficacy not established.

Conditional Use and Restrictions

Patients with severe liver impairment or severe renal impairment (Glomerular Filtration Rate < 30 mL/min) are subject to conditional use and require a modified, reduced-frequency dosing schedule due to reduced drug clearance. Use is not recommended for women who are pregnant or breastfeeding because loratadine and its metabolite are excreted into human milk. Additionally, the medicine must be discontinued at least 48 hours before allergy skin tests as it may interfere with test results.

What should I know about interactions with other medicines?

The official interaction profile for Claratyne (Loratadine) focuses on substances that alter its metabolic clearance, which can significantly modify the drug’s systemic exposure.

Exposure-Modifying Interactions

Interacting Substance Official Interaction Outcome
Ketoconazole Concurrent use is associated with substantially increased plasma concentrations of Loratadine.
Erythromycin Concurrent use is associated with substantially increased plasma concentrations of Loratadine and its metabolite.
Cimetidine Concurrent use is associated with substantially increased plasma concentrations of Loratadine.
Food Administration with a single dose of food increases the systemic AUC (bioavailability) of Loratadine by approximately 40% to 48%.

These pharmacokinetic interactions are linked to the inhibition of the CYP3A4 and CYP2D6 enzyme systems responsible for Loratadine's metabolism. All known inhibitors of these enzymes may potentially increase the exposure of Loratadine.

Pharmacodynamic and Procedural Constraints

The profile documents a pharmacodynamic interaction risk: combining Loratadine with other Central Nervous System (CNS) depressants may lead to additive sedation. However, controlled studies have not found alcohol to potentiate the effects of Loratadine on psychomotor performance. A strict timing rule is documented, requiring administration to be stopped 48 hours prior to any allergy skin testing procedures to prevent interference with diagnostic results.

Population-Specific Considerations

Patients with severe hepatic impairment (liver disease) or chronic renal impairment show increased plasma concentrations and reduced clearance of Loratadine, which is a critical consideration in these populations.

Mechanism of Action

Interrupting the Histamine Cascade: Peripheral H1 Inverse Agonism

Loratadine acts through selective inverse agonism on peripheral Histamine H1 receptors . This mechanism actively stabilizes the H1 receptor in its inactive state, directly blocking the ability of histamine to bind and initiate the corresponding physiological activity. By modulating H1 signaling on endothelial cells and peripheral sensory nerves, this action limits the increase in vascular permeability (fluid leakage) and attenuates the signaling of peripheral sensory nerves.

System Selectivity and H1-Independent Pathway Modulation

A critical mechanistic domain is the drug's limited ability to cross the Blood-Brain Barrier ( BBB), which results in high selectivity for peripheral targets and minimal interaction with CNS H1 receptors. Furthermore, the molecule demonstrates an H1-independent mechanism by modulating intracellular signaling factors like the NF-kappa B pathway. This effect suppresses the activity and release of specific cytokines and chemokines, which contributes to modulating the overall inflammatory pathway activity.

Dosage and Administration Information

How to Use Claratyne: Official Administration Guidelines

Administration of Claratyne, which contains the active ingredient Loratadine, follows principles detailed in established guidelines. The medication is designated for oral administration only, available across multiple forms including tablets, oral solution, and chewable/disintegrating tablets.


Standard Dosing and Frequency

The established regimen is centered on a once-daily schedule (qDay) for all approved populations, reflecting its long-acting pharmacological profile. The standard dose for adults and children six years of age and older is 10 mg once every 24 hours. For children between two and six years old, the typical dose is 5 mg once daily, often administered via the oral syrup or solution form. The administration is generally flexible and may be taken without regard to mealtime (with or without food).


Population-Specific Use and Adjustments

Specific frequency adjustments exist for patients with impaired organ function. For adults and children weighing more than 30 kg who have severe hepatic (liver) impairment or severe renal (kidney) impairment (glomerular filtration rate <30 mL/min), the recommended dose is 10 mg every other day. This reduced frequency is applied to accommodate potentially decreased clearance of the active substance.


Administration Protocol

Adherence to the once-daily frequency is required to ensure the maximum daily dose of 10 mg is not exceeded. If a dose is missed, it should be taken when remembered, but the subsequent dose must be maintained at the regular schedule; double dosing is not permitted. Furthermore, administration is typically discontinued at least 48 hours prior to any skin-prick allergy testing, as the antihistamine can interfere with the results.

Recent Clinical Evidence

Claratyne: Recent Clinical Evidence

Claratyne (loratadine) is a second-generation, non-sedating antihistamine widely studied for the relief of allergic symptoms. Research focuses on its efficacy for allergic rhinitis (hay fever) and chronic spontaneous urticaria (hives).


Efficacy for Allergic Rhinitis

Clinical trials, including multi-center, randomized controlled trials (RCTs), have evaluated loratadine's ability to affect symptoms associated with seasonal allergic rhinitis (SAR). Key findings indicate a demonstrable difference from placebo in reducing overall nasal and non-nasal symptom scores, such as sneezing, runny nose, and itchy, watery eyes.

  • Symptom Scoring: Studies track mean changes in total symptom severity scores (TSS) over a treatment period, reporting greater average reductions in the active treatment groups compared to placebo.
  • Onset of Effect: Research suggests that symptomatic relief may be observed within the first day of treatment and is consistently maintained throughout the standard treatment course.

Safety and Tolerability Profiles

Loratadine is generally considered to be associated with low rates of sedation due to its limited ability to cross the blood-brain barrier, a characteristic distinguishing second-generation antihistamines.

Population Studied Safety Focus in Research
Pediatric (Aged 2-6) Safety and appropriate dosing for young children are established; research monitors for unexpected adverse reactions.
Drug Interactions Clinical trials and post-marketing surveillance investigate potential interactions, especially with drugs affecting liver enzymes (CYP3A4 and CYP2D6), which could alter loratadine's concentration.

Reported adverse events observed in clinical trials are typically mild and transient, with the most common being headache, dry mouth, and fatigue. Serious side effects are rarely reported.

Key Studies & References

  1. Loratadine - StatPearls (for general safety, pharmacokinetics, and dosing context)
  2. Clinical Practice Guideline: Allergic Rhinitis (used for general context and classification of antihistamines)

Frequently Asked Questions (FAQ)

Common questions about Claratyne (FAQ)


Q: Is Claratyne considered a non-drowsy allergy medication?

A: Official information generally describes the active ingredient, loratadine, as a non-sedating antihistamine. Clinical studies indicate that when Claratyne is used according to the product directions, the risk of drowsiness (somnolence) is low.


Q: What is the approved age range for Claratyne use?

A: The approved age range for Claratyne depends on the product form. For the standard oral tablet, use is typically indicated for children 6 years of age and older. The oral solution or syrup formulation's approved labeling includes its use in children as young as 2 years old.


Q: Is Claratyne a first-generation or second-generation antihistamine?

A: The active ingredient in Claratyne, loratadine, is classified in regulatory documents as a second-generation antihistamine. This classification indicates that the drug has a mechanism of action that is less likely to cause noticeable drowsiness.


Q: Are there any age restrictions on the combination Claratyne and decongestant products?

A: Yes, official labeling notes that combination products, which contain both loratadine and a decongestant (like pseudoephedrine), have specific age restrictions. Official labeling indicates use for adults and children 12 years of age and older.


Q: Does Claratyne contain lactose or gluten?

A: The active ingredient itself, loratadine, does not contain lactose or gluten. However, the inactive ingredients used in specific product forms, such as tablets or chewables, may include these substances. The list of inactive ingredients, found on the product packaging, should be reviewed.


Q: Is Claratyne used for general allergy relief?

A: According to official documentation, Claratyne is indicated for general allergy relief, specifically for the symptoms associated with seasonal allergic rhinitis (such as hay fever) and perennial allergic rhinitis (year-round allergies). It is also used for the relief of symptoms related to chronic urticaria (hives).


Q: Does Claratyne help with skin rashes or hives?

A: Yes, Claratyne is officially indicated for the relief of symptoms and signs of chronic urticaria, which is the medical term for chronic hives.


Q: How quickly does Claratyne start to work?

A: Official information regarding the time it takes for Claratyne to begin working indicates that the effects generally begin within one to three hours after taking the dose. The peak antihistaminic effect typically occurs between eight and twelve hours.


Q: Does Claratyne have any known food or drink interactions?

A: Regulatory sources generally state that there are no known significant interactions between the active ingredient loratadine and food or non-alcoholic beverages. Claratyne can typically be taken without regard to mealtime.


Q: What are the most common side effects reported for Claratyne?

A: The most frequently reported side effects in adults in clinical trials include headache, somnolence (drowsiness), and fatigue. These are the most common events noted in regulatory documentation.


Q: Can Claratyne cause feelings of nervousness or anxiety?

A: Yes, regulatory documentation lists nervousness as a common side effect reported in both adult and pediatric populations using loratadine.


Q: Is it normal to feel a bit dizzy after taking Claratyne?

A: Dizziness is documented in official source materials as a reported adverse event, though it is considered very rare. Patients should review the safety information provided with the product for details on the incidence of adverse effects.


Q: Are there any reported interactions between Claratyne and common pain relievers?

A: Official sources do not describe a significant interaction between loratadine and common pain relievers such as ibuprofen or acetaminophen. However, it is important to review the full list of ingredients of any combination pain relief product.


Q: Does Claratyne interact with cold and flu remedies?

A: Caution is noted in regulatory documents regarding combination with cold and flu remedies. This is especially true if the remedy contains other medications that can cause drowsiness or sedation, as combining them with Claratyne may contribute to an increased risk of sedation.


Q: Can Claratyne affect sleep patterns?

A: While Claratyne is classified as non-sedating, both somnolence (drowsiness) and insomnia (difficulty sleeping) are listed as reported adverse events in official safety documentation. These effects are infrequently reported.


Q: Is Claratyne available over-the-counter?

A: Yes, the active ingredient in Claratyne, loratadine, has been approved by major regulatory bodies in many countries for over-the-counter (OTC) availability.


Q: Is there a Claratyne liquid formulation for children?

A: Yes, Claratyne is available in an oral solution or syrup formulation. This liquid form is often the product indicated for younger children.


Q: What does official research say about Claratyne's effectiveness for hay fever?

A: Official clinical trials indicate that loratadine provides relief for the symptoms associated with seasonal allergic rhinitis, commonly known as hay fever. This is supported by regulatory indications.


Q: Have studies been done on long-term use of Claratyne?

A: Studies on the sustained use of loratadine and other second-generation antihistamines have examined periods up to six months. This research indicates that the medication is generally well-tolerated and have not shown a loss of effectiveness over that period.


Q: Is Claratyne used for non-allergy conditions, according to official information?

A: The officially approved uses for Claratyne are exclusively for conditions related to allergies, specifically the symptoms of allergic rhinitis (seasonal and perennial) and chronic urticaria (hives).


Q: Can Claratyne be used during specific seasons, like spring?

A: Yes, Claratyne is indicated for seasonal allergic rhinitis, making it appropriate for use during specific high-pollen seasons such as spring, when symptoms like hay fever are common.


Q: Does taking Claratyne with other medications make its side effects worse?

A: Regulatory warnings state that combining loratadine with other medications that have a sedating effect may increase the risk of side effects like drowsiness or dizziness. It is important that patients review the Drug Interactions section of the product labeling.


Q: What is the official information regarding Claratyne use during pregnancy?

A: Loratadine use during pregnancy has been reviewed by regulatory bodies. Consultation with a healthcare professional is important before use to discuss the potential benefits and risks.


Q: Are there specific warnings about Claratyne and breastfeeding?

A: Official sources note that small amounts of loratadine and its metabolites may pass into breast milk. Due to its low levels and non-sedating profile, it is often discussed as an appropriate choice for use while breastfeeding.


Q: Is it true that some Claratyne products contain decongestants?

A: Yes, there are combination products available that include both loratadine and a decongestant, such as pseudoephedrine. These are usually labeled with a 'D' suffix to denote the added decongestant ingredient.


Q: Does Claratyne affect blood pressure?

A: Loratadine alone is not generally associated with changes in blood pressure. However, combination products that include a decongestant as a second active ingredient may carry warnings related to blood pressure due to the effects of that added ingredient.


Q: Does Claratyne help with indoor allergies like dust mites?

A: Claratyne is indicated for perennial allergic rhinitis, which covers year-round allergy symptoms. This includes those caused by indoor allergens like dust mites, molds, and pet dander.


Q: What are the contraindications listed in official documents for Claratyne?

A: Official regulatory documents list contraindications, which are conditions that prevent use of the medicine. The primary contraindication is a known hypersensitivity or allergy to loratadine, desloratadine, or any other component found in the formulation.


Q: Is Claratyne included in any official guidelines for treating allergies?

A: Yes, loratadine is commonly cited in various national and international allergy treatment guidance. It is often recommended as a first-line option for managing the symptoms of allergic rhinitis.


Q: Can Claratyne be used for pet allergies?

A: As Claratyne is indicated for perennial allergic rhinitis, it is commonly used to help relieve year-round symptoms, including those triggered by exposure to pet dander.


Q: What is the official information on Claratyne and alcohol consumption?

A: Official product information states that caution should be exercised regarding alcohol consumption while taking loratadine. Although the drug is generally non-sedating, alcohol consumption can increase the risk of side effects like dizziness and drowsiness.


Q: Does Claratyne cause weight gain?

A: Regulatory documentation lists increased appetite as an uncommon adverse event associated with the use of loratadine. This is an uncommon side effect that could potentially be linked to minor weight changes.


Q: Is there a chance of developing tolerance to Claratyne over time?

A: Studies examining the long-term use of loratadine indicate that the drug maintains its effectiveness over a sustained period of use. The evidence suggests that tolerance to the drug's effects does not typically develop.


Q: How is Claratyne processed by the body?

A: Claratyne is absorbed from the digestive tract and then processed, or metabolized, primarily in the liver. It is then largely eliminated from the body as inactive compounds through both urine and feces.


Q: Is Claratyne commonly used for allergic conjunctivitis (eye allergies)?

A: Yes, Claratyne is indicated for the symptoms of allergic rhinitis, which include ocular symptoms. These symptoms often include watery, itchy, and burning eyes associated with allergic conjunctivitis.


Q: What are the signs of an allergic reaction to Claratyne itself?

A: Regulatory documents list signs of a hypersensitivity reaction, which may include rash, hives (urticaria), and swelling of the face, lips, mouth, tongue, or throat.


Q: Are there different strengths of Claratyne available?

A: Yes, the standard oral tablet form is most widely available in the 10 mg strength. The oral solution or syrup is typically formulated to allow for lower dosages, such as 5 mg per dose, for children.


Q: Can I take Claratyne if I have a heart condition, based on regulatory information?

A: Official labeling lists cardiac side effects such as tachycardia (fast heart rate) and palpitations as very rare adverse events. Patients with pre-existing heart conditions are advised to review the product information with a healthcare professional regarding suitability.


Q: What are the differences between Claratyne and Claritin?

A: Claratyne and Claritin contain the exact same active ingredient, which is loratadine. Any differences between the two products are typically limited to the inactive ingredients or branding specific to the country of sale.


Q: Is Claratyne a steroid?

A: No, Claratyne is classified as an antihistamine. It works by blocking the action of histamine in the body, which is a different mechanism from how steroid medications work to reduce inflammation.


Q: Do studies suggest Claratyne works well for chronic hives?

A: The official indication for loratadine includes the relief of symptoms and signs associated with chronic idiopathic urticaria, which is a type of chronic hives, suggesting regulatory confidence in its effectiveness for this condition.


Q: Does Claratyne interact with herbal supplements?

A: Official regulatory data on specific interactions between loratadine and herbal supplements is very limited. Patients are generally advised to inform a healthcare provider about all supplements they are taking.


Q: What types of allergic rhinitis does Claratyne treat, according to the label?

A: The official label specifies that Claratyne is indicated for the treatment of symptoms related to both seasonal allergic rhinitis (occurring during specific times of the year) and perennial allergic rhinitis (occurring year-round).


Q: What is the evidence regarding Claratyne use in older adults?

A: While Claratyne is considered generally suitable for older adults, regulatory warnings advise that special caution or a dose adjustment may be necessary for individuals in this population who have existing liver or kidney impairment.

How should Claratyne be stored and disposed of?

How to Store and Dispose of Claratyne

Official regulatory documents define specific conditions for the storage and disposal of loratadine to ensure product stability and household safety.


Storage Requirements

Condition Requirement Constraint
Temperature Store at Controlled Room Temperature, typically 20^circ to 25 C. Liquid must be kept from freezing.
Environment Protect from excessive moisture and excess heat. Store in the original container, tightly closed.
Safety Keep the medicine out of sight and reach of children (mandatory). Do not use if the original packaging or seal is compromised.

Disposal

Official labeling instructs users to ask a pharmacist or doctor for guidance on how to dispose of any medicine that is unused or has passed its expiration date. Disposal must be in accordance with local regulations, and generally, the product should not be thrown into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Claratyne found in:

A-Z Index: